Announcing the Launch of HistAI CELLDX Keratinocytic Lesions Suite: A Huge Leap in Cancer Diagnosis*

In honor of World Cancer Day, we are thrilled to unveil a groundbreaking advancement in cancer diagnostics—the "HistAI CELLDX Keratinocytic Lesions Suite." This cutting-edge tool, empowered by an expansive proprietary dataset of 6,353 whole slide images (WSIs), stands as one of the most comprehensive resources available in the field. With rigorous validation on 1,459 slides, our state-of-the-art algorithm is designed to deliver unparalleled precision and reliability, making a significant impact in real-world scenarios.

Showing the Power of AI in Pathology

The HistAI CELLDX Keratinocytic Lesions Suite exemplifies our commitment to harnessing the power of artificial intelligence to revolutionize pathology. By leveraging this vast dataset, we are not only enhancing the accuracy of keratinocytic lesion detection but also contributing to the global fight against cancer. Our technology supports the Close the Care Gap initiative, striving to bridge disparities in cancer care and diagnosis worldwide.

Commitment to Open Access and Collaboration

True to our open access policy, we are excited to offer free evaluations of this revolutionary AI tool. We believe that by making advanced diagnostic tools accessible to all, we can foster greater collaboration and innovation within the medical community. We invite you to experience the transformative capabilities of the HistAI CELLDX Suite firsthand by visiting CELLDX.

A Milestone in Our Journey

This release marks a significant milestone in our ongoing journey to provide cutting-edge solutions to the global community of pathologists. Our goal is to empower medical professionals with the tools they need to make accurate diagnoses, ultimately improving patient outcomes and advancing the field of cancer research.

Join Us in the Fight Against Cancer

As we commemorate World Cancer Day, we call on the global medical community to unite in our efforts to innovate and close the care gap. Together, we can make strides towards a future where precision diagnostics and equitable cancer care are the norms, not the exceptions. Let's continue to push the boundaries of what's possible in medical technology and work hand in hand to combat this devastating disease.

*For research use only. Not for primary diagnosis.